Cytokinetics Investors Face Nov. 17 Deadline in Shareholder Suits Over Aficamten Disclosures
The suits accuse the company of hiding REMS-related risks that could have delayed FDA review of aficamten.
Overview
- Rosen Law Firm, Holzer & Holzer, Bragar Eagel & Squire, and the Schall Law Firm issued new notices urging shareholders to contact them about lead‑plaintiff positions.
- Complaints allege the company guided investors to expect second‑half 2025 FDA approval based on a September 26, 2025 PDUFA date while not disclosing that its NDA was filed without a REMS.
- Press materials cite a May 6, 2025 earnings call describing multiple pre‑NDA FDA meetings on safety and the decision to proceed without a REMS.
- The proposed class period spans December 27, 2023 through May 6, 2025, and the filings claim investors incurred losses when these details emerged.
- Notices emphasize that no class has been certified and state that investors may seek recovery through contingency‑fee arrangements.